摘要
2型糖尿病是一种多基因遗传性慢性代谢疾病,是威胁全球健康的主要疾病之一.因其复杂的病理机制和多样的影响因素使其在临床诊疗中效果差异较大.本文在现有研究的基础上分析了不同治疗方案的差异,比较了常规的单药治疗和序贯治疗存在的差异,而以二肽基肽酶-4(dipeptidyl peptidase-4,DPP-4)抑制剂和钠-葡萄糖协同转运蛋白-2(sodium-glucose co-transporter 2,SGLT2)抑制剂为代表的新型口服降糖药在早期联合治疗中表现出了较为明显的优势,为2型糖尿病治疗提供了新思路,并具有一定的临床参考价值.
Type 2 diabetes mellitus is a multigenic hereditary chronic metabolic disease which is one of the major diseases that threaten global health.Due to its complex pathological mechanism and diverse influencing factors,it vary greatly in clinical diagnosis and treatment.Based on the existing research,this paper explores the differences between different treatment options,and finds that there are different degrees of defects in conventional monotherapy and sequential therapy,while the new oral hypoglycemic agents,such as DPP-4i and SGLT-2i,show a significant advantage in the early stage combination therapy.It is a good new insight for the treatment of type 2 diabetes,and has certain reference value for clinical treatment.
作者
李文娟
姬秋和
LI Wen-juan;JI Qiu-he(Department of Endocrinology and Metabolism,Xijing Hospital Affiliated to Air Force Military Medical University,Xi'an Shanxi 710032,China)
出处
《药品评价》
CAS
2018年第A01期18-22,共5页
Drug Evaluation
